ImageneBio Inc (IMA) Stock Ticker
Market factors today
Unlock the full IMA picture
About ImageneBio Inc
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
IMA stock facts
| Ticker symbol | IMA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $53.2M |
| CEO | Kristin Yarema |
| Employees | 18 |
| Headquarters | San Diego, CA, US |
| IPO date | 1998-02-27 |
| Website | www.inmagenebio.com |
What you can see for IMA on Tickr
Live IMA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IMA report.
Rankings
FAQ
What is the ticker symbol for ImageneBio Inc?
The ticker symbol for ImageneBio Inc is IMA, listed on the NASDAQ Global Market.
What is IMA?
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was…